Literature DB >> 12476873

Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil.

Deborah Lidgate1, Michael Brandl, Marites Holper, Allassan Abubakari, Xiaoyang Wu.   

Abstract

Studies were performed to (1) evaluate whether the presence of iron affected the physicochemical properties of mycophenolate mofetil (MMF) and mycophenolic acid (MPA), and (2) determine whether alteration of these properties was indicative of formation of an MMF-iron complex. The solubility, stability (chemical reactivity), and partitioning properties of MMF and MPA were evaluated over a pH range of 2-7 in the presence and absence of ferrous sulfate. In addition, the solubility and partitioning properties of MMF were assessed after the MMF drug product, CellCept capsules, was combined with an iron tablet (Fero-Gradumet, ferrous sulfate, tablets). The results of studies showed that: The solubility of MMF in the presence of ferrous sulfate was generally unaffected over a pH range of 2-7; a small increase in solubility was observed in pH 5.2 buffer solution. The solubility of MPA decreased in pH 5.2 and 7.0 buffer solutions. Both MMF and MPA were more stable in the presence of ferrous sulfate at pH 2.0; ferrous sulfate had no effect on the stability of MMF and MPA at pH 7.0. Overall, the partitioning of MMF and MPA was unaffected by the addition of ferrous sulfate. The solubility and partitioning of MMF from CellCept capsules combined with Fero-Gradumet (ferrous sulfate) tablets showed a twofold increase in aqueous solubility of MMF as well as increased concentration of MMF in both the n-octanol and aqueous phases, leading to a decrease in the octanol/water partition coefficient due to a reduction in pH of the aqueous phase. Based on these results, it was concluded that the physicochemical properties of MMF and MPA were generally not affected by the presence of ferrous sulfate. Further, the presence of ferrous sulfate did not suggest the formation of an MMF-iron complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476873     DOI: 10.1081/ddc-120015361

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  4 in total

1.  Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.

Authors:  Paul V Bernhardt; Piao Chin; Philip C Sharpe; Jing-Yan C Wang; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2005-11-08       Impact factor: 3.358

2.  No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

Authors:  Olesja Rissling; Petra Glander; Pia Hambach; Marco Mai; Susanne Brakemeier; Daniela Klonower; Fabian Halleck; Eugenia Singer; Eva-Vanessa Schrezenmeier; Michael Dürr; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

Review 3.  Iron therapy for renal anemia: how much needed, how much harmful?

Authors:  Walter H Hörl
Journal:  Pediatr Nephrol       Date:  2007-01-06       Impact factor: 3.714

4.  Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients.

Authors:  Tomasz Urbanowicz; Ewa Straburzyńska-Migaj; Veronica Casadei; Michał Bociański; Marek Jemielity
Journal:  Ann Transplant       Date:  2020-01-24       Impact factor: 1.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.